Tourmaline Bio (TRML) Stock Price, News & Analysis

Company Overview

Tourmaline Bio, Inc. (NASDAQ:TRML) is a clinical-stage biopharmaceutical company focused on developing next-generation antibody therapeutics for oncology and immune-mediated diseases. The company’s proprietary glycoengineering platform is designed to optimize antibody effector functions and improve therapeutic indices by precisely modifying glycan structures. Headquartered in Cambridge, Massachusetts, Tourmaline Bio leverages cutting-edge research to advance a pipeline of novel monoclonal antibodies and antibody-drug conjugates aimed at addressing high unmet medical needs.

The company’s R&D strategy centers on enhancing antibody activity while minimizing off-target effects. By employing site-specific glycan remodeling, Tourmaline Bio seeks to bolster antibody-dependent cellular cytotoxicity and enhance tumor cell clearance. This platform approach supports both in-house candidate development and external partnerships, enabling collaborations with larger pharmaceutical companies to co-develop or out-license lead assets. The flexibility of the platform allows for rapid iteration and optimization across multiple therapeutic targets.

Tourmaline Bio’s pipeline features several preclinical and clinical-stage assets, including a bispecific antibody in Phase 1 development for solid tumors and an engineered anti-CD20 antibody for B-cell malignancies. The company has also initiated exploratory programs in autoimmune indications, where glycoengineered antibodies may offer improved safety profiles over conventional biologics. With manufacturing scaled through state-of-the-art CMC capabilities in North America and Europe, Tourmaline Bio maintains strategic partnerships to support global clinical development and eventual commercial readiness.

Founded in 2018 by a team of biochemists and immunologists, Tourmaline Bio is led by President and CEO Michael Scharpe, whose prior leadership roles include senior management positions at established biotech firms. The executive team is rounded out by Nancy Lee, Chief Financial Officer, and Dr. David Normoyle, Chief Scientific Officer, each bringing extensive experience in antibody drug discovery and corporate finance. Together, they guide Tourmaline Bio’s mission to translate innovative antibody engineering into transformative therapies for patients worldwide.

Key Stats

• Today's Range: $16.11 to $16.52
• 50-Day Range: $14.54 to $19.90
• 52-Week Range: $11.56 to $29.79
• Volume: 59,085 shs
• Average Volume: 256,004 shs
• Market Capitalization: $430.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.33
• Consensus Rating: Buy

Tourmaline Bio Stock Analysis - MarketRank™

Tourmaline Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 630th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tourmaline Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tourmaline Bio is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tourmaline Bio is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tourmaline Bio has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.78% of the float of Tourmaline Bio has been sold short.

Short Interest Ratio / Days to Cover

Tourmaline Bio has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Tourmaline Bio has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tourmaline Bio does not currently pay a dividend.

Dividend Growth

Tourmaline Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.78% of the float of Tourmaline Bio has been sold short.

Short Interest Ratio / Days to Cover

Tourmaline Bio has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Tourmaline Bio has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Tourmaline Bio this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRML Stock Analysis - Frequently Asked Questions

How have TRML shares performed this year?

Tourmaline Bio's stock was trading at $20.28 on January 1st, 2025. Since then, TRML stock has decreased by 17.3% and is now trading at $16.7750.

How were Tourmaline Bio's earnings last quarter?

Tourmaline Bio, Inc. (NASDAQ:TRML) posted its quarterly earnings data on Friday, May, 2nd. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.02.

How do I buy shares of Tourmaline Bio?

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tourmaline Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/02/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRML
• Previous Symbol: NASDAQ:TRML
• CIK: 1827506
• Web: N/A
• Phone: 502-398-9250
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $49.33
• High Stock Price Target: $70.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +194.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.75%
• Return on Assets: -26.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 33.87
• Quick Ratio: 33.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.71 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 25,680,000
• Free Float: 22,346,000
• Market Cap: $430.78 million
• Optionable: Optionable
• Beta: 2.00